FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:            | 3235-0287 |
|------------------------|-----------|
| Estimated average burd | len       |
| hours per response.    | 0.5       |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| issuer that is inte | of equity securities of the<br>ended to satisfy the<br>se conditions of Rule<br>nstruction 10. | 9        |   |          |   |                                       |
|---------------------|--|----------|---|----------|---|---------------------------------------|
| 1. Name and Addre   | ess of Reporting Person  | n*       | 2. Issuer Name <b>and</b> Ticker or Trading Symbol USANA HEALTH SCIENCES INC [ USNA ] | (Check   | ationship of Reporting Pers<br>all applicable) Director | ,,                                    |
| (Last)              | (First)  | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 03/04/2024                           | X        | Officer (give title below)                              | 10% Owner<br>Other (specify<br>below) |
| (Street)            | ARKWAY BLVD  |          | 4. If Amendment, Date of Original Filed (Month/Day/Year)                              | 6. Indiv | ridual or Joint/Group Filing<br>Form filed by One Rep   | orting Person                         |
| SALT LAKE<br>CITY   | UT   | 84120    |   |          | Form filed by More than                                 | n One Reporting Person                |
| (City)              | (State)  | (Zip)    |   |          |   |                                       |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transac<br>Code (Ir<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |           | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | Beneficial<br>Ownership |
|---------------------------------|--|---|---------------------------------|---|--|---------------|-----------|--|---|-------------------------|
|                                 |  |   | Code                            | v | Amount   | (A) or<br>(D) | Price     | Transaction(s)<br>(Instr. 3 and 4)                                     |   | (Instr. 4)              |
| Common Stock                    | 03/04/2024                                 |   | S                               |   | 491  | D             | \$49.0748 | 0  | D   |                         |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | '    |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D) (Instr. 3, 4<br>and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                                     | Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | Ownership<br>Form:<br>Direct (D) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|--|---|---|------|---|--|-----|--|--------------------|--|-------------------------------------|--------------------------------------|--|----------------------------------|--|
|  |   |   | Code | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |                                      | Transaction(s)<br>(Instr. 4)   |                                  |  |

**Explanation of Responses:** 

Remarks:

/s/ Joshua Foukas, Attorney-in-

Fact

\*\* Signature of Reporting Person Dat

03/05/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).